Due to its integral role in metabolism, FXR is a drug target for several diseases, including nonalcoholic steatohepatitis (12), also known as metabolic dysfunction–associated steatohepatitis (13), primary biliary cholangitis (14), type II diabetes (2) and atherosclerosis (15). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.